Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 known ✓ | P22748 | 4/20 | 0.43 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.33 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8442297 | 0.82 | CA4 (0.46) | CA4 | |
| SCHEMBL3219620 | 0.80 | CA4 (0.44) | CA4 | |
| SCHEMBL16393916 | 0.77 | CA4 (0.46) | CA4 | |
| SCHEMBL9495140 | 0.76 | CA4 (0.33) | CA4CA2 | |
| Potassium Ion SCHEMBL28038691 | 0.76 | CA4 (0.39) | CA4 | |
| SCHEMBL7094704 | 0.75 | CA4 (0.40) | CA4 | |
| SCHEMBL27555518 | 0.75 | CA4 (0.40) | CA4 | |
| SCHEMBL5923886 | 0.75 | CA4 (0.48) | CA4 | |
| SCHEMBL27888587 | 0.73 | CA4 (0.41) | CA4 | |
| SCHEMBL2030766 | 0.72 | CA4 (0.63) | CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114790472-B | Fructosyl curcumin, preparation method and application | 上海龙殷生物科技有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-12006355-B2 | Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-11 | — | — | US | disclosed |
| CN-114790472-B | Fructosyl curcumin, preparation method and application | 上海龙殷生物科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20230107569-A1 | METHOCARBAMOL COMPOSITIONS AND RELATED METHODS | EXELA STERILE MEDICINES LLC | 2023-04-06 | — | — | US | disclosed |
| CN-114790472-A | Fructose glycosylated curcumin, preparation method and application | 上海龙殷生物科技有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20220169708-A1 | NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif) | THE TRUSTEES OF DARTMOUTH COLLEGE | 2022-06-02 | — | — | US | disclosed |
| US-11225514-B2 | Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200231659-A1 | NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-23 | — | — | US | disclosed |
| WO-2018222587-A1 | NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-06 | — | — | WO | disclosed |
| EP-2277546-B1 | Stable ready to use injectable paracetamol formulation | UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB S A (GR) | 2015-07-15 | — | — | EP | disclosed |
| US-8877817-B2 | Stable ready to use injectable paracetamol formulation | TSETI IOULIA (GR) | 2014-11-04 | — | — | US | disclosed |
| US-20130210922-A1 | STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION | UNIPHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2013-08-15 | — | — | US | disclosed |
| EP-2389923-B1 | Stable ready to use injectable paracetamol formulation | UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB S A (GR) | 2013-01-30 | — | — | EP | disclosed |
| US-20120190750-A1 | STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2012-07-26 | — | — | US | disclosed |
| EP-2389923-A1 | Stable ready to use injectable paracetamol formulation | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) | 2011-11-30 | — | — | EP | disclosed |
| WO-2011144335-A1 | STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2011-11-24 | — | — | WO | disclosed |
| EP-2277546-A1 | Stable ready to use injectable paracetamol formulation | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. (GR) | 2011-01-26 | — | — | EP | disclosed |
| US-6096870-A | ISOLATION OF DAIRY PRODUCT POLYPEPTIDES; PROVIDING SAMPLE, PASSING SAMPLE THROUGH ION EXCHANGE RESIN, RECOVERING ELUATE, ELUTING IMMUNOGLOBULIN, LACTOGLOBULIN, LACTALBUMIN, SERUM ALBUMIN, LACTOFERRINS, AND LACTOPEROXIDASE | SEPRAGEN CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0712632-A1 | REMEDY FOR DISEASES CHARACTERIZED BY ABNORMAL ACCUMULATION OR ACTIVATION OF LEUKOCYTE | TORAY INDUSTRIES, INC. (JP) | 1996-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231659-A1 | NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif) | CFTR, CFH, VSIR | CA4 982/4885CA1 4027/4885CA2 1282/4885 |
| US-20220169708-A1 | NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif) | CFTR, CFH, VSIR | CA4 982/4885CA1 4027/4885CA2 1282/4885 |
| US-11225514-B2 | Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif) | CFTR, CFH, VSIR | CA4 982/4885CA1 4027/4885CA2 1282/4885 |
| US-12006355-B2 | Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif) | CFTR, CFH, VSIR | CA4 982/4885CA1 4027/4885CA2 1282/4885 |
| US-20230107569-A1 | METHOCARBAMOL COMPOSITIONS AND RELATED METHODS | ELANE, MIF, SLC11A2 | CA4 3443/4885CA1 4080/4885CA2 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.